OBJECTIVES: To determine the efficacy and tolerance of interferon-gamma-1b (IFN-gamma) for the prevention of death related to infection in patients with burn injury who were at risk for infection. The positive anti-infective effects of IFN-gamma observed in animal models and in clinical studies provided the rationale for this study. DESIGN: Randomized, double-blind, placebo-controlled, phase III multicenter trial, with a group sequential design, conducted at 23 European burn centers. PATIENTS: Two hundred sixteen patients with major critical burn (Abbreviated Burn Severity Index score of > or = 7). INTERVENTION: Patients were randomized to receive IFN-gamma (100 microg) or placebo daily by subcutaneous injection for up to 90 days. MEASUREMENT AND MAIN RESULTS: The primary end point (the incidence of death related to infection within 90 days from the start of treatment) was similar in the two treatment groups. There were no significant differences between the two treatments in any of the secondary end points (all causes of mortality at 90 days, incidence of infectious complications, duration of intensive care unit or hospital stay, and scar formation at 90 days). CONCLUSION: IFN-gamma did not protect burn patients from infections or decrease the mortality from infections.
RCT Entities:
OBJECTIVES: To determine the efficacy and tolerance of interferon-gamma-1b (IFN-gamma) for the prevention of death related to infection in patients with burn injury who were at risk for infection. The positive anti-infective effects of IFN-gamma observed in animal models and in clinical studies provided the rationale for this study. DESIGN: Randomized, double-blind, placebo-controlled, phase III multicenter trial, with a group sequential design, conducted at 23 European burn centers. PATIENTS: Two hundred sixteen patients with major critical burn (Abbreviated Burn Severity Index score of > or = 7). INTERVENTION: Patients were randomized to receive IFN-gamma (100 microg) or placebo daily by subcutaneous injection for up to 90 days. MEASUREMENT AND MAIN RESULTS: The primary end point (the incidence of death related to infection within 90 days from the start of treatment) was similar in the two treatment groups. There were no significant differences between the two treatments in any of the secondary end points (all causes of mortality at 90 days, incidence of infectious complications, duration of intensive care unit or hospital stay, and scar formation at 90 days). CONCLUSION:IFN-gamma did not protect burn patients from infections or decrease the mortality from infections.
Authors: Joslyn M Albright; Christopher S Davis; Melanie D Bird; Luis Ramirez; Hajwa Kim; Ellen L Burnham; Richard L Gamelli; Elizabeth J Kovacs Journal: Crit Care Med Date: 2012-04 Impact factor: 7.598
Authors: Alan E Rosenbach; Piyush Koria; Jeremy Goverman; Kenneth T Kotz; Amit Gupta; Ming Yu; Shawn P Fagan; Daniel Irimia; Ronald G Tompkins Journal: Clin Transl Sci Date: 2011-02 Impact factor: 4.689
Authors: Christopher S Davis; Scott E Janus; Michael J Mosier; Stewart R Carter; Jeffrey T Gibbs; Luis Ramirez; Richard L Gamelli; Elizabeth J Kovacs Journal: Ann Surg Date: 2013-06 Impact factor: 12.969
Authors: Christopher S Davis; Joslyn M Albright; Stewart R Carter; Luis Ramirez; Hajwa Kim; Richard L Gamelli; Elizabeth J Kovacs Journal: J Burn Care Res Date: 2012 Jan-Feb Impact factor: 1.845
Authors: R J Rentenaar; J de Metz; M Bunders; P M Wertheim-van Dillen; D J Gouma; J A Romijn; H P Sauerwein; I J ten Berge; R A van Lier Journal: Clin Exp Immunol Date: 2001-09 Impact factor: 4.330